Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   IRANIAN JOURNAL OF PUBLIC HEALTH   AUGUST 2014 , Volume 43 , Number SUPPLEMENT 2; Page(s) 43 To 43.
 
Paper: 

PREPARATION AND IN VITRO EVALUATION OF ANTITUMOR ACTIVITY OF TGF?L3-SEB AS A LIGAND-TARGETED SUPERANTIGEN

 
 
Author(s):  YOUSEFI FOROUGH*, MUSAVI SEYYED FAZLOLLAH, SIADAT SEYED DAVAR, IMANI FOOLADI ABBAS ALI, AMANI JAFAR, ASLANI MOHAMMAD MEHDI, AZIZI SARAJI ALIREZA
 
* DEPARTMENT OF MEDICAL BACTERIOLOGY, PASTEUR INSTITUTE OF IRAN, TEHRAN, IRAN
 
Abstract: 

Background: In this study, we explored the antitumor potency of tumor-targeted super antigens (TTS) strategy; we designed and produced a fusion protein as a new antitumor candidate by fusing the third loop (L3) of transforming growth factor ? (TGFaL3) genetically to staphylococcal enterotoxin type B and evaluated in vitro antitumor activities against murine breast cancer cell line.
Methods: We designed and prepared TGF
aL3-SEB chimeric protein and evaluated superantigenic activity, binding property to cancer cell over expressing epidermal growth factor receptor (EGFR) and in vitro antitumor activities.
Results: Cloning of tgf
al3-seb was confirmed by colony- PCR, enzymatic digestion and sequencing. The recombinant TGFaL3-SEB fusion protein with molecular weights of 31 kDa was expressed and confirmed by anti-his western-blot analysis. TGFaL3-SEB fusion protein attached to A431 cell line with proper affinity and induced dose-dependent cytotoxicity against cancer cells expressing EGFR in vitro.
Conclusion: TGF
aL3-SEB fusion protein was successfully designed, expressed and purified. This chimeric fusion protein exhibits potent in vitro antitumor activity. So, these results indicate that TGFaL3-SEB might be a promising anticancer candidate for cancer immunotherapy and further efforts are needed to explore this potential therapeutic strategy.

 
Keyword(s): BREAST CANCER, STAPHYLOCOCCAL ENTEROTOXIN TYPE B (SEB)
 
References: 
  • ندارد
 
  Yearly Visit 40
 
Latest on Blog
Enter SID Blog